Expression of a proliferation-inducing ligand in B-cell chronic lymphocytic leukemia and its clinical significance
10.3760/cma.j.issn.1009-9921.2014.03.008
- VernacularTitle:增殖诱导配体在慢性B淋巴细胞白血病中的表达及其临床意义
- Author:
Guihua ZHANG
;
Lingsong CHEN
;
Qiurong ZHANG
;
Jinge XU
- Publication Type:Journal Article
- Keywords:
Leukemia,B-cell,chronic;
A proliferation-inducing ligand;
Prognostic indicator
- From:
Journal of Leukemia & Lymphoma
2014;23(3):156-159
- CountryChina
- Language:Chinese
-
Abstract:
Objective To quantitatively analyze the mRNA and protein expression level of a proliferation-inducing ligand (APRIL) and investigate its clinical significance in peripheral blood mononuclear cells and plasma from newly diagnosed patients with B-cell chronic lymphocytic leukemia (B-CLL).Methods The mRNA of the target gene in 32 B-CLL patients and 15 health controls was quantified with real-time fluorescence quantitative polymerase chain reaction (RFQ-PCR) and protein by enzyme-linked immunosorbent assay (ELISA).Results APRIL mRNA was assayed with RFQ-PCR,the intra-and inter-batch reproducibility showed the coefficient of variation (CV) were 1.69 ％-6.98 ％ and 6.49 ％-10.27 ％,respectively.The expressions of APRIL mRNA and protein in patients with B-CLL were significantly higher than those in control (P ＜ 0.05),and significant difference was noted among the comparable stages in the arms (P ＜ 0.05).The expression of APRIL mRNA and protein in TDI (treatment-demand-indicator) arm was significantly higher than those in non-TDI arm (P ＜ 0.05).Conclusions APRIL may be involved in the formation and development of B-CLL and be an influence factor for disease staging.Thus,APRIL may be a prognostic indicator as well as the therapy target for the disease.
